Skip to main content
Log in

Liposomal Influenza Vaccine

A Viewpoint by Janet E. McElhaney

  • Adis New Drug Profile
  • Guest Commentary
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Gravenstein S, Drinka P, Duthie EH, et al. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc 1994; 42: 245–51

    PubMed  CAS  Google Scholar 

  2. Mbawuike IN, Acuna C, Caballero D, et al. Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A. Cell Immunol 1996; 173: 64–78

    Article  PubMed  CAS  Google Scholar 

  3. Powers DC, McElhaney JE, Florendo Jr OA, et al. Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. J Infect Dis 1997; 175: 342–51

    Article  PubMed  CAS  Google Scholar 

  4. Powers DC. Summary of a clinical trial with liposome-ad-juvanted influenza A virus vaccine in elderly adults. Mech Ageing Dev 1997; 93: 179–88

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

McElhaney, J.E. Liposomal Influenza Vaccine. BioDrugs 11, 145–146 (1999). https://doi.org/10.2165/00063030-199911020-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199911020-00009

Keywords

Navigation